AZD0120

AZD0120 is listed on ClinicalTrials.gov as an intervention in 2 registered phase 3 trials sponsored by AstraZeneca and Alexion Pharmaceuticals, Inc., in multiple myeloma. A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.